Cue Health Stock

Cue Health P/B

P/B (Price-to-Book Ratio) of Cue Health (HLTHQ) as of Aug 7, 2026.

P/B

0.00

YoY

130.37%

Last updated:

P/B (Price-to-Book Ratio) of Cue Health is 2026 0.00 . P/B (Price-to-Book Ratio) of Cue Health was 2025 0.00 . It decreases by 130.37% higher compared to the previous year.
Access this data via the Eulerpool API

Cue Health Stock analysis

What does Cue Health do? Cue Health Inc. is a San Diego-based company specialized in the development and distribution of smart, mobile diagnostic devices. The company was founded in 2010 by Ayub Khattak and Dan Sullivan and has since expanded into various sectors. Cue Health's main business is the development of diagnostic devices that allow end-users to quickly and easily perform diagnostic tests. With a handheld device and proprietary software, customers can perform a wide range of tests in many areas, including tests for flu, colds, inflammatory diseases, sexually transmitted diseases, and COVID-19. Cue Health's business model is based on the idea of providing user-friendliness and portability in the field of diagnostics. With the technology, patients can independently perform diagnostic tests without having to visit a doctor. This not only saves time but also reduces costs for the customer. Since its founding, Cue Health has expanded into several sectors. In addition to the handheld diagnostic device, the company also offers solutions for the healthcare services sector. Through partnerships with biotech companies and medical institutions, the company assists in the development and marketing of diagnostic tests. An important part of Cue Health's history is the development of COVID-19 tests. The company quickly responded to develop a solution for COVID-19 tests that are both safe and easier to use. The Cue COVID-19 Test Kit complies with the requirements of the US Food and Drug Administration and is used in the USA. The test only requires a simple nasal swab, which is then inserted into the handheld device. Within minutes, the user receives the test result. Cue Health intends to continue expanding its technology to offer users a wider range of diagnostic test solutions. The previous tests have shown that the company is capable of delivering innovative solutions to the diagnostics market. The ability to receive fast, accurate, and affordable diagnostic solutions is invaluable for many people, especially those in hard-to-reach locations and without direct access to medical professionals. Overall, Cue Health is a highly innovative company specializing in excellent diagnostic technology and products for the healthcare industry. The products and services of Cue Health have the potential to revolutionize healthcare for all by making diagnostic tests safer, faster, and more convenient. Cue Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cue Health stock

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Cue Health since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Cue Health with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Cue Health

All Key Metrics — Cue Health